Skip to content
Surf Wiki
Save to docs
general

From Surf Wiki (app.surf) — the open knowledge base

2-Oxo-LSD


Column 1
2-Oxy-LSD; O-LSD; 2-Keto-LSD; 2-Oxo-2,3-dihydro-LSD; N,N-Diethyl-6-methyl-2-oxo-9,10-didehydro-2,3-dihydroergoline-8β-carboxamide
.mw-parser-output .plainlist ol,.mw-parser-output .plainlist ul{line-height:inherit;list-style:none;margin:0;padding:0}.mw-parser-output .plainlist ol li,.mw-parser-output .plainlist ul li{margin-bottom:0}None
IUPAC name
(6aR,9R)-N,N-diethyl-7-methyl-5-oxo-4,5a,6,6a,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
101635360
C20H25N3O2
339.439 g·mol−1
Interactive image
SMILES
CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3C4=C(C2=C1)C=CC=C4NC3=O)C
InChI
InChI=1S/C20H25N3O2/c1-4-23(5-2)20(25)12-9-14-13-7-6-8-16-18(13)15(19(24)21-16)10-17(14)22(3)11-12/h6-9,12,15,17H,4-5,10-11H2,1-3H3,(H,21,24)/t12-,15?,17-/m1/s1Key:LEPCXKMUXAQZKG-XURPUJGUSA-N

2-Oxo-LSD, also known as 2-oxy-LSD or 2-keto-LSD, or more fully as 2-oxo-2,3-dihydro-LSD, is a lysergamide and metabolite of the psychedelic drug lysergic acid diethylamide (LSD). It is a metabolite of LSD in both humans and various animal species, although there are important differences in LSD metabolism and relative proportions of metabolites between species.

2-Oxo-LSD is formed directly from LSD in the body and is also possibly an intermediate in the generation of LSD's major metabolite 2-oxo-3-hydroxy-LSD (O-H-LSD), which is present in urine at concentrations 4 to 40 times those of LSD in humans. However, O-H-LSD may also form from other metabolites, such as 3-hydroxy-LSD. The specific enzymes responsible for the generation of individual LSD metabolites like 2-oxo-LSD are largely unknown. However, several cytochrome P450 enzymes were investigated and implicated in the formation of O-H-LSD in 2019.

2-Oxo-LSD showed absence of various pharmacological effects in animals. In contrast to LSD and certain other metabolites like 13-hydroxy-LSD, 2-oxo-LSD failed to produce LSD-like electroencephalogram (EEG) changes in rabbits. 2-Oxo-LSD at a dose of 300 μg orally produced no psychoactive effects in a human subject who had previously responded to 30 μg LSD. It was concluded that 2-oxo-LSD shows no LSD-like activity in the central nervous system and hence is inactive. 2-Oxo-LSD's derivative O-H-LSD showed profound loss of activity at the serotonin 5-HT2 receptors compared to LSD in vitro. 2-Oxo-LSD is said to readily enter the brain.

2-Oxo-LSD contains most of the clinically used dopamine D2-like receptor agonist and antiparkinsonian agent ropinirole within its chemical structure.

2-Oxo-LSD was first described in the scientific literature by Julius Axelrod and colleagues in 1957.

  • Substituted lysergamide

  • 2-Oxo-3-hydroxy-LSD

  • 2,3-Dihydro-LSD

  • Nor-LSD

  • Lysergic acid ethyl-2-hydroxyethylamide (LEO)

  • Lysergic acid ethylamide (LAE)

  • 13-Hydroxy-LSD

  • 14-Hydroxy-LSD

  • 2-Bromo-LSD

  • 2-Iodo-LSD

  • 2-Oxo-LSD-Isomer Design

Want to explore this topic further?

Ask Mako anything about 2-Oxo-LSD — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report